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COMMENTARY Open Access
Diagnosis and management of hyponatraemia:
AGREEing the guidelines
Alexander P Maxwell
Abstract
Hyponatraemia is a common electrolyte disorder associated with significant complications and controversies regarding
its optimal management. Clinical practice guidelines and consensus statements have attempted to provide clinicians
with evidence-based diagnostic and treatment strategies for hyponatraemia. Recently published guidance documents
differ in their methods employed to review the quality of available evidence. Nagler et al. used the Appraisal of
Guideline for Research and Evaluation (AGREE II) instrument in a systematic review of guidelines and consensus
statements for the diagnosis and management of hyponatraemia. Nagler and colleagues highlighted the variability in
methodological rigour applied to guideline development and inconsistencies between publications in relation to
management of hyponatraemia (including the recommended rate of correction of a low serum sodium concentration).
These differences could cause confusion for practising physicians managing patients with hyponatraemia.
Please see related article: http://www.biomedcentral.com/1741-7015/12/231.
Keywords: Hyponatraemia, Guidelines, Systematic review
Background
Hypotonic hyponatraemia (serum sodium concentra-
tion <135 mmol/L with low osmolality) is the most
common electrolyte abnormality in hospitalised adult
patients [1]. The diagnosis and management of hypona-
traemia may be complex, costly, and controversial.
Hyponatraemia has diverse aetiologies and is additionally
defined clinically by its duration, “acute” (<48 hours) versus
“chronic” (>48 hours), and by the presence or absence of
symptoms. Management can be challenging particularly in
the emergency setting where different treatment options
may help or indeed harm individual patients. It is perhaps
surprising that management of this electrolyte disorder
has a limited evidence base in part due to the paucity of
high quality randomised controlled trials. Multiple clinical
practice and consensus guidelines for the diagnosis and
management of hyponatraemia have been published by
local, national, and international organisations. These
guidelines represent genuine efforts to address the diag-
nostic challenges and controversies in its management,
particularly in relation to the rate of correction for the
serum sodium concentration. The systematic review by
Nagler et al. [2], reviewing the quality of recent published
guidelines and consensus statements for diagnosis and
treatment of hyponatraemia, has highlighted important var-
iations in both their development and recommendations.
Guidelines of hyponatraemia treatment
Hypotonic hyponatraemia is a clinical state where there
is a relative excess of water to sodium content in the
extracellular fluid [3]. Acute hyponatraemia is clinically
important as it can cause significant morbidity and mor-
tality associated with rapid development of symptomatic
cerebral oedema. Prompt treatment to raise the serum
sodium concentration in this setting is life-saving. Chronic
hyponatraemia, even if asymptomatic, is associated with
many adverse outcomes including prolonged hospitalisa-
tion, gait instability, falls, fractures, and increased bone loss
[4,5]. Diverse strategies to correct chronic hyponatraemia
have been recommended and success of such treatment is
dependent on the underlying aetiology for hyponatraemia.
Overly rapid correction of chronic hyponatraemia may
trigger an osmotic demyelination syndrome resulting in
serious neurological deficits and death [6].
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The methodological quality of guideline development
and consensus statements can be assessed using the
Appraisal of Guidelines for Research and Evaluation
(AGREE II) process [7]. This tool is used to systematic-
ally evaluate six guideline domains including scope,
stakeholder involvement, editorial independence, rigour of
development, clarity, and applicability. Nagler et al. identi-
fied five clinical practice guidelines and five consensus
statements after a comprehensive search of English and
non-English publications, guideline databases, and pro-
fessional society websites [2]. Their recommendations
differed with respect to classification of hyponatraemia,
diagnostic tests, doses of saline to use for correction,
limits for the rise in serum sodium concentration, and the
most appropriate second line therapies for management.
The overall quality of these publications (measured by the
AGREE tool) was mixed.
Should we be surprised that individual hyponatraemia
guidelines “failed” this test of quality? Arguably, the
diagnosis and management of hyponatraemia cannot be
subjected to this sort of rigorous analysis because of the
low level of evidence available to help various expert
panels and guideline groups write internationally consist-
ent advice. For example, hyponatraemia occurring within
48 hours is an arbitrary cut-off for determining the
presence of acute hyponatraemia, the desired rate of
correction for hyponatraemia in most settings is not
universally agreed, availability of certain recommended
therapies is country dependent and impacted by differing
regulatory indications for drugs, and even the biochemical
threshold for defining hyponatraemia varies widely in the
literature. Furthermore, many of the clinical algorithms
require initial assessment of the extracellular fluid volume
to determine if a hyponatraemic patient is hypovolaemic,
euvolaemic, or hypervolaemic. In practice, this physical
examination of fluid balance can be subject to misinter-
pretation if the clinical signs are subtle.
The applicability of guidelines remains a major issue.
The target audience are the clinicians who may infrequently
encounter an ill patient with either acute symptomatic
hyponatraemia requiring urgent correction or a patient
with profound chronic hyponatraemia and additional risk
factors (malnourished, hypokalaemia, history of alcoholism)
for the osmotic demyelination syndrome. It is improbable
that clinicians would always be able to quickly access or
indeed assimilate the comprehensive advice in scholarly
recent publications on diagnosis and treatment of hypona-
traemia. For instance, Spasovski et al. (European Guideline
Development Group) produced a 39 page clinical practice
guideline [8] and Verbalis et al. (Expert Panel Recommen-
dations) published an extensive narrative review running
to 42 pages [9]. These guidelines are freely available but
have several important differences, particularly in relation
to the drug treatment of chronic hyponatraemia, which
may lead to some confusion for clinicians. If appropriate,
fluid restriction is used in the management of chronic
hyponatraemia but this is frequently of limited efficacy.
Additional pharmacological agents have been used, in-
cluding demeclocycline, lithium, urea, loop diuretics, and
vaptan drugs (conivaptan and tolvaptan) [8,9]. Tolvaptan
has been used more extensively in the USA for the
treatment of hypervolaemic and euvolaemic hypona-
traemia compared to Europe, where tolvaptan’s licence
is restricted to hyponatraemia caused by the syndrome of
inappropriate anti-diuretic hormone [10]. The European
clinical practice guideline has been widely endorsed by
European specialist societies for nephrologists, endocri-
nologists, and intensive care medicine clinicians.
In the “real world”, the non-expert doctor who initially
recognises and responds to severe hyponatraemia (serum
sodium concentration <120 mmol/L) in a critically ill
patient will often be a junior trainee working “out of
routine office hours”. In this emergency setting, the
doctor may have limited immediate access to important
additional diagnostic tests, e.g., serum and urine osmo-
lality and urine electrolytes. Urgent treatment decisions
may need to be taken to manage symptoms such as
confusion and seizures, with incomplete patient history
and diagnostic information. There is a general consensus
that hypertonic saline is effective in the immediate man-
agement of acute symptomatic hyponatraemia but avail-
able guidelines differ on the volumes and rates of saline
infusion. Ultimately, it is clinical judgement rather than
adherence to a particular guideline that will determine
an individual patient’s treatment. Intuitive clinical algo-
rithms, with proven efficacy, would help to encourage
“best practice” in the diagnosis and management of
hyponatraemia.
Conclusions
Improving both the accuracy of diagnosis and the appro-
priate management of hyponatraemia are important
goals given the morbidity and mortality associated with
this common electrolyte disorder. A greater consistency
in future clinical practice guidelines would represent a
significant educational achievement and, crucially, would
help clinicians to pick the best options for patients with
hyponatraemia.
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